US Bancorp DE Has $101,000 Stock Position in Certara, Inc. (NASDAQ:CERT)

US Bancorp DE lowered its stake in Certara, Inc. (NASDAQ:CERT) by 18.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,451 shares of the company’s stock after selling 2,124 shares during the period. US Bancorp DE’s holdings in Certara were worth $101,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Brown Brothers Harriman & Co. acquired a new position in shares of Certara during the third quarter worth $27,292,000. Kopion Asset Management LLC lifted its holdings in Certara by 46.0% in the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after buying an additional 175,005 shares during the period. Principal Financial Group Inc. lifted its holdings in Certara by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company’s stock valued at $5,660,000 after buying an additional 15,739 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after buying an additional 1,128,006 shares during the period. Finally, Vontobel Holding Ltd. bought a new stake in Certara in the fourth quarter valued at $1,295,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Up 4.7 %

Shares of NASDAQ:CERT opened at $10.92 on Monday. The firm has a fifty day moving average price of $12.57 and a two-hundred day moving average price of $11.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -54.60, a PEG ratio of 9.29 and a beta of 1.60. Certara, Inc. has a one year low of $9.41 and a one year high of $19.18.

Wall Street Analyst Weigh In

CERT has been the subject of several recent research reports. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company. Barclays boosted their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. William Blair reiterated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Stephens reaffirmed an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.